货号:GS40313
Grisnilimab is an investigational immunoglobulin G2a (IgG2a) monoclonal antibody targeting CD7. It is classified as an anti-CD7 monoclonal antibody and is associated with research into Wilms' tumor (WT1), a pediatric kidney cancer. The designation "(WT1)" likely refers to the Wilms' tumor 1 gene/protein context of its study, not its direct target.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
冉凯凯